Cardiotoxicity of Chemotherapeutic Agents

Gregg M. Lanier, M.D. (Editor)
Lehigh Valley Health Network, Allentown, USA
Division of Cardiology, Department of Medicine,
Westchester Medical Center and New York Medical College,
Valhalla, USA

Jalaj Garg, M.D. (Editor)
Lehigh Valley Health Network, Allentown, Pennsylvania, USA

Neeraj Shah (Editor)
Lehigh Valley Health Network, Allentown, USA

Series: Cancer Etiology, Diagnosis and Treatments, Cardiology Research and Clinical Developments
BISAC: MED062000

Clear

$160.00

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Cardiotoxicity is a well-established complication of antineoplastic agents. Cardiomyopathy resulting from anthracyclines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more specific than conventional therapies, has revolutionized oncology therapy and dramatically changed cancer prognosis. However, some of these therapies have introduced an assortment of cardiovascular complications. At times, these devastating outcomes have only become apparent after drug approval and have limited the use of potent therapies. There is a growing need for better testing platforms, both for cardiovascular toxicity screening and for elucidating mechanisms of cardiotoxicity of approved cancer therapies.

Our book is a comprehensive summary of information of numerous antineoplastic agents and their cardiovascular adverse effects. Cardiac oncology is an exciting and ever-changing field, and we have attempted to synthesize information from all the major and relevant studies in the field in our book.

The authors hope that their book serves as a valuable reference in the field of cardiac oncology for the clinicians who are actively involved in the management of patients receiving antineoplastic agents, including primary care physicians, cardiologists, cardiology fellows in training and oncologists. (Imprint: Nova Biomedical)

Preface

Chapter 1. Introduction: Cardiotoxicity of Chemotherapeutic Agents
Jalaj Garg MD FESC, Neeraj Shah MD MPH and Gregg M. Lanier MD (Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)

Chapter 2. Alkylating Agents
Jalaj Garg MD, Varun Mittal MD, Neeraj Shah MD, Abhishek Sharma, Vidhu Anand MD and Gregg M. Lanier MD (Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)

Chapter 3. Antimetabolites
Jalaj Garg MD FESC, Varun Mittal MD, Neeraj Shah MD MPH, Abhishek Sharma MD, Vidhu Anand MD and Gregg M. Lanier MD (Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)

Chapter 4. Antitumor Antibiotics: Bleomycin and Mitoxantrone
Rahul Gupta MD, Rahul Chaudhary MD, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M. Lanier MD (Queens Cardiac Care, Queens, USA, and others)

Chapter 5. Antitumor Antibiotics: Anthracyclines, a Mechanism of Cardiotoxicity
Rahul Chaudhary MD, Rahul Gupta MBBS, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M Lanier MD (Division of Medicine, Sinai Hospital of Baltimore, USA, and others)

Chapter 6. Antitumor Antibiotics: Anthracyclines, Cardiotoxicity and Associated Risk Factors
Rahul Chaudhary MD, Rahul Gupta MBBS, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M. Lanier MD (Division of Medicine, Sinai Hospital of Baltimore, USA, and others)

Chapter 7. Antitumor Antibiotics: Anthracyclines and Minimizing Cardiotoxicity
Rahul Chaudhary MD, Rahul Gupta MBBS, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M. Lanier MD (Division of Medicine, Sinai Hospital of Baltimore, USA, and others)

Chapter 8. Antitumor Antibiotics: Newer Anthracyclines
Rahul Gupta MD, Rahul Chaudhary MD, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M. Lanier MD. (Queens Cardiac Care, Queens, USA, and others)

Chapter 9. Microtubule Inhibitors
Brijesh Patel DO, Rahul Gupta MBBS, Jalaj Garg MD FESC, Naveen Sablani MD MS, Ronak Patel MD FACC and Gregg M. Lanier MD (Division of Cardiology, Lehigh valley Health Network, Allentown, USA, and others)

Chapter 10. Hormonal Therapy
Jalaj Garg MD FESC, Mahek Shah MD, Rahul Chaudhary MD, Rahul Gupta MBBS, Ronak Patel MD FACC and Gregg M Lanier MD (Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)

Chapter 11. Immunotherapy
Nayan Agarwal MD, Rahul Gupta MBBS, Abhishek Sharma MD, Rudhir Tandon MD, Rahul Chaudhary MD, Raman Dusaj MD and Gregg M. Lanier MD (Division of Cardiology, University of Florida, Gainesville, USA, and others)

Chapter 12. Monoclonal Antibodies
Jalaj Garg MD FESC, Nayan Agarwal MD, Neeraj Shah MD MPH, Rahul Gupta MBBS, Nainesh C Patel MD FACC and Gregg M Lanier MD FACC (Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)

Chapter 13. Tyrosine Kinase Inhibitors
Mahek Shah MD, Rahul Gupta MBBS, Rahul Chaudhary MD, Nainesh C Patel MD FACC and Gregg M Lanier MD (Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)

Chapter 14. Topoisomerase-1 Inhibitors and Miscellaneous Drugs
Rahul Chaudhary MD, Nikhil Mukhi MD, Rahul Gupta MBBS, Jalaj Garg MD FESC, Philip Carson MD, Neeraj Shah MD MPH, Gregg M. Lanier MD (Division of Medicine, Sinai Hospital of Baltimore, USA, and others)

About the Editors

Index

We hope that our book serves as a valuable reference in the field of cardiac oncology for the clinicians who are actively involved in the management of patients receiving, antineoplastic agents, including primary care physician, cardiologist, cardiology fellows in training and oncologist.

If you have any questions or comments with regards to this book, please fill out the form below. Thank you!

You have not viewed any product yet.